CL2016002303A1 - Compuestos químicos. - Google Patents
Compuestos químicos.Info
- Publication number
- CL2016002303A1 CL2016002303A1 CL2016002303A CL2016002303A CL2016002303A1 CL 2016002303 A1 CL2016002303 A1 CL 2016002303A1 CL 2016002303 A CL2016002303 A CL 2016002303A CL 2016002303 A CL2016002303 A CL 2016002303A CL 2016002303 A1 CL2016002303 A1 CL 2016002303A1
- Authority
- CL
- Chile
- Prior art keywords
- chemical compounds
- carboxamida
- pirazin
- enac
- copd
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101100532722 Ovis aries SCNN1B gene Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 101150082646 scnn1a gene Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>COMPUESTOS DERIVADOS DE PIRAZIN-CARBOXAMIDA Y SUS SALES; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA EL TRATAMIENTO DE UN ESTADO DE ENFERMEDAD MEDIADO POR ENAC TAL COMO ASMA Y EPOC.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954674P | 2014-03-18 | 2014-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002303A1 true CL2016002303A1 (es) | 2017-01-13 |
Family
ID=52780553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002303A CL2016002303A1 (es) | 2014-03-18 | 2016-09-13 | Compuestos químicos. |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US9873678B2 (es) |
| EP (1) | EP3119752B1 (es) |
| JP (1) | JP6502469B2 (es) |
| KR (1) | KR102296041B1 (es) |
| CN (1) | CN106103423B (es) |
| AP (1) | AP2016009447A0 (es) |
| AR (1) | AR099790A1 (es) |
| AU (1) | AU2015233195B2 (es) |
| CA (1) | CA2941807C (es) |
| CL (1) | CL2016002303A1 (es) |
| CR (1) | CR20160479A (es) |
| CY (1) | CY1120509T1 (es) |
| DK (1) | DK3119752T3 (es) |
| DO (1) | DOP2016000232A (es) |
| EA (1) | EA029952B1 (es) |
| ES (1) | ES2679618T3 (es) |
| GT (1) | GT201600190A (es) |
| HR (1) | HRP20181123T1 (es) |
| HU (1) | HUE039425T2 (es) |
| IL (1) | IL247610B (es) |
| LT (1) | LT3119752T (es) |
| ME (1) | ME03056B (es) |
| MX (1) | MX368577B (es) |
| NI (1) | NI201600134A (es) |
| NZ (1) | NZ724063A (es) |
| PE (1) | PE20170205A1 (es) |
| PH (1) | PH12016501808B1 (es) |
| PL (1) | PL3119752T3 (es) |
| PT (1) | PT3119752T (es) |
| RS (1) | RS57487B1 (es) |
| SG (1) | SG11201607751SA (es) |
| SI (1) | SI3119752T1 (es) |
| SM (1) | SMT201800378T1 (es) |
| SV (1) | SV2016005278A (es) |
| TR (1) | TR201810207T4 (es) |
| TW (1) | TWI687410B (es) |
| UY (1) | UY36034A (es) |
| WO (1) | WO2015140527A1 (es) |
| ZA (1) | ZA201607136B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7608847B2 (ja) * | 2021-01-27 | 2025-01-07 | 三菱瓦斯化学株式会社 | エポキシ樹脂硬化剤、エポキシ樹脂組成物、及び塗料 |
| GB202406247D0 (en) | 2024-05-03 | 2024-06-19 | Enterprise Therapeutics Ltd | Compounds and pharmaceutical compositions |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3577418A (en) | 1969-02-12 | 1971-05-04 | Merck & Co Inc | Pyrazinamide derivatives and processes for their preparation |
| US3573306A (en) | 1969-03-05 | 1971-03-30 | Merck & Co Inc | Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides |
| IE52345B1 (en) | 1981-02-02 | 1987-09-16 | Ici Plc | Alkanolamine derivatives |
| DE3361244D1 (de) | 1982-01-29 | 1986-01-02 | Ici Plc | Alkanolamine derivatives |
| GB8810933D0 (en) | 1987-05-26 | 1988-06-15 | Ici America Inc | Heterocyclic compounds |
| GB8810934D0 (en) | 1987-05-26 | 1988-06-15 | Ici America Inc | Amides |
| US4803206A (en) | 1988-03-07 | 1989-02-07 | Schering Corporation | Antihypertensive acylpyrazines |
| GB8812343D0 (en) | 1988-05-25 | 1988-06-29 | Ici America Inc | Amino compounds |
| GB8812342D0 (en) | 1988-05-25 | 1988-06-29 | Ici America Inc | Bicyclic compounds |
| SK112899A3 (en) | 1997-02-26 | 2001-05-10 | Pfizer | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor |
| GB9930557D0 (en) | 1999-12-23 | 2000-02-16 | Rolic Ag | Optically active materials |
| CA2408408C (en) | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
| AR039555A1 (es) | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20040087571A1 (en) | 2002-10-30 | 2004-05-06 | Pfizer Inc | Methods of using CCR1 antagonists as immunomodulatory agents |
| EP1581499A1 (en) | 2002-12-20 | 2005-10-05 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| MX2007004536A (es) | 2004-10-13 | 2007-07-17 | Univ Connecticut | Ligandos de lipido canabinergico. |
| GB0511065D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526240D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| EP2332933A1 (en) | 2007-05-07 | 2011-06-15 | Novartis AG | Epithelial sodium channel (ENaC) inhibitors |
| BRPI0820669A2 (pt) | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| MX2010012441A (es) | 2008-05-13 | 2010-12-06 | Novartis Ag | Derivados de acido 3,5-diamino-6-cloro-pirazin-2-carboxilico y su uso como bloqueadores del canal de sodio epitelial para el tratamiento de enfermedades de las vias respiratorias. |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| WO2011028740A1 (en) * | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| US9505735B2 (en) | 2012-06-21 | 2016-11-29 | Whitehead Institute For Biomedical Research | Compounds for treating infectious diseases |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
-
2015
- 2015-03-16 UY UY0001036034A patent/UY36034A/es not_active Application Discontinuation
- 2015-03-17 US US15/124,393 patent/US9873678B2/en active Active
- 2015-03-17 MX MX2016011681A patent/MX368577B/es active IP Right Grant
- 2015-03-17 SM SM20180378T patent/SMT201800378T1/it unknown
- 2015-03-17 CR CR20160479A patent/CR20160479A/es unknown
- 2015-03-17 AP AP2016009447A patent/AP2016009447A0/en unknown
- 2015-03-17 EP EP15713339.8A patent/EP3119752B1/en active Active
- 2015-03-17 ES ES15713339.8T patent/ES2679618T3/es active Active
- 2015-03-17 TW TW104108476A patent/TWI687410B/zh active
- 2015-03-17 CA CA2941807A patent/CA2941807C/en active Active
- 2015-03-17 PE PE2016001600A patent/PE20170205A1/es unknown
- 2015-03-17 JP JP2017500446A patent/JP6502469B2/ja active Active
- 2015-03-17 HU HUE15713339A patent/HUE039425T2/hu unknown
- 2015-03-17 LT LTEP15713339.8T patent/LT3119752T/lt unknown
- 2015-03-17 KR KR1020167028483A patent/KR102296041B1/ko active Active
- 2015-03-17 DK DK15713339.8T patent/DK3119752T3/en active
- 2015-03-17 SG SG11201607751SA patent/SG11201607751SA/en unknown
- 2015-03-17 NZ NZ724063A patent/NZ724063A/en not_active IP Right Cessation
- 2015-03-17 PT PT157133398T patent/PT3119752T/pt unknown
- 2015-03-17 PL PL15713339T patent/PL3119752T3/pl unknown
- 2015-03-17 RS RS20180833A patent/RS57487B1/sr unknown
- 2015-03-17 EA EA201691641A patent/EA029952B1/ru not_active IP Right Cessation
- 2015-03-17 SI SI201530318T patent/SI3119752T1/en unknown
- 2015-03-17 TR TR2018/10207T patent/TR201810207T4/tr unknown
- 2015-03-17 ME MEP-2018-185A patent/ME03056B/me unknown
- 2015-03-17 HR HRP20181123TT patent/HRP20181123T1/hr unknown
- 2015-03-17 AU AU2015233195A patent/AU2015233195B2/en active Active
- 2015-03-17 WO PCT/GB2015/050765 patent/WO2015140527A1/en not_active Ceased
- 2015-03-17 CN CN201580013691.1A patent/CN106103423B/zh active Active
- 2015-03-18 AR ARP150100820A patent/AR099790A1/es unknown
-
2016
- 2016-09-04 IL IL247610A patent/IL247610B/en not_active IP Right Cessation
- 2016-09-07 DO DO2016000232A patent/DOP2016000232A/es unknown
- 2016-09-13 NI NI201600134A patent/NI201600134A/es unknown
- 2016-09-13 CL CL2016002303A patent/CL2016002303A1/es unknown
- 2016-09-14 GT GT201600190A patent/GT201600190A/es unknown
- 2016-09-14 SV SV2016005278A patent/SV2016005278A/es unknown
- 2016-09-16 PH PH12016501808A patent/PH12016501808B1/en unknown
- 2016-10-17 ZA ZA2016/07136A patent/ZA201607136B/en unknown
-
2017
- 2017-12-13 US US15/840,339 patent/US10336725B2/en active Active
-
2018
- 2018-07-18 CY CY20181100750T patent/CY1120509T1/el unknown
-
2019
- 2019-05-10 US US16/408,741 patent/US10954211B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| ECSP16088985A (es) | Procesos para preparar un inhibidor de jak1 y nuevas formas de este | |
| CL2016001963A1 (es) | Heteroarilos inhibidores de syk | |
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CL2017003163A1 (es) | Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2015001265A1 (es) | Compuestos derivados de 2-aminoquinazolina sustituidos; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7 y/o tlr8 tal como infecciones viricas. | |
| CR20170564A (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| ECSP17023281A (es) | Inhibidores de mk2 y sus usos | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| BR112016028773A2 (pt) | processos para preparação de compostos antivirais | |
| CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
| DK3461821T3 (da) | Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere | |
| MX2016010675A (es) | Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa). | |
| MX2016009135A (es) | Heteroarilos y usos de estos. | |
| DK3235819T3 (da) | Pyrrolopyrimidinforbindelser, der er anvendelige som JAK-inhibitorer | |
| DK3188717T3 (da) | Formulering, der omfatter partikler | |
| EP3322311A4 (en) | EXOTHERMIC EVAPORATOR | |
| MX2017001553A (es) | Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. | |
| HUE037210T2 (hu) | Triciklusos heterociklusos vegyületek, mint foszfoinozitid 3-kináz inhibitorok | |
| MX2017007377A (es) | Compuestos organicos. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 |